GLP1R and early-onset autosomal dominant Alzheimer disease: Although the improvement started to appear before 6 months, it was more obvious by 52 weeks, suggesting that GLP-1 analogs may positively influence cognition in Alzheimer’s disease over a prolonged period of treatment, and the preserved MRI outcomes may be compatible with a possible neuroprotective effect.